NewAmsterdam Pharma Company N.V. (NAMS) Total liabilities 2022–2025
NewAmsterdam Pharma Company N.V. (NAMS) total liabilities at each fiscal year-end, per SEC filings.
$85.9MFY2025 · since FY2022: $48.4M → $85.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $85.9M | -19.9% |
| FY2024 | $107.1M | +82.5% |
| FY2023 | $58.7M | +21.2% |
| FY2022 | $48.4M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More NAMS financial trends
NAMS RevenueNAMS Net incomeNAMS Net marginNAMS Gross profitNAMS Gross marginNAMS Operating incomeNAMS Operating marginNAMS Operating cash flowNAMS Free cash flowNAMS Capital expendituresNAMS Return on equityNAMS Stock buybacksNAMS Dividends paidNAMS Total assetsNAMS Shareholders’ equityNAMS overview →